早期乳腺癌新辅助免疫检查点抑制剂联合化疗:系统综述与荟萃分析
该系统综述与荟萃分析纳入9项随机临床试验共5114例早期乳腺癌患者,评估新辅助免疫检查点抑制剂联合化疗的疗效与安全性。结果显示,在三阴性乳腺癌中,无论PD-L1状态如何,联合ICIs均与pCR率改善相关(绝对改善>10%);在HR+/ERBB2-肿瘤中,仅PD-L1阳性人群的pCR率改善(绝对改善+12.2%);ERBB2+肿瘤中未见获益。在达到pCR或存在残留病灶的三阴性乳腺癌患者中,新辅助ICIs与EFS改善相关;辅助ICIs未显示数值上的改善。
要点
- 在三阴性乳腺癌中,新辅助ICIs联合化疗与pCR率改善相关,无论PD-L1状态如何,绝对改善>10%。
- 在HR+/ERBB2-肿瘤中,仅PD-L1阳性人群的pCR率改善(绝对改善+12.2%),ERBB2+肿瘤中未见获益。
- 在三阴性乳腺癌中,新辅助ICIs在达到pCR和存在残留病灶的患者中均与EFS改善相关;辅助ICIs未显示数值上的改善。
核心结论
- 这些发现提示,新辅助ICIs治疗可改善早期三阴性乳腺癌和PD-L1阳性HR+/ERBB2-肿瘤的疗效结局,且安全性可接受;然而,辅助ICIs未观察到获益。
- 鉴于ICIs相关的经济与毒性成本,未来研究应优先识别最可能从新辅助化疗联合ICIs中获益的患者。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed数据库(截至2023年12月10日),纳入评估早期乳腺癌(新)辅助ICIs联合化疗的随机临床试验。
- 共纳入9项随机临床试验,涉及5114例患者(2097例三阴性乳腺癌,1924例HR+/ERBB2-肿瘤,1115例ERBB2+肿瘤)。
- 由2名评价者提取数据,进行提取个体患者数据的荟萃分析和试验水平的随机效应荟萃分析。
- 采用分层Cox比例风险回归模型估计风险比。
主要发现
- 在三阴性乳腺癌中,加用ICIs与pCR率改善相关,无论PD-L1状态如何(绝对改善>10%)。
- 在HR+/ERBB2-肿瘤中,ICIs仅在PD-L1阳性人群中与pCR率改善相关(绝对改善+12.2%),在ERBB2+肿瘤中未观察到获益。
- 在三阴性乳腺癌达到pCR的患者中,加用ICIs与EFS改善相关(HR 0.65;95%CI 0.42-1.00),5年EFS为92.0%(ICIs组)vs 88.0%(无ICIs组)。
- 在存在残留病灶的患者中,ICIs也显示更好的EFS(HR 0.77;95%CI 0.61-0.98),5年EFS为63.3%(ICIs组)vs 56.1%(无ICIs组)。
- 辅助ICIs在达到pCR或存在残留病灶的患者中均未显示数值上的改善(所有HR>1)。
关键数值与推荐
- 新辅助治疗期间,ICIs相关3级或以上免疫相关不良事件的发生率为10.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent studies have investigated the combination of immune checkpoint inhibitors (ICIs) with (neo)adjuvant chemotherapy in early-stage breast cancer. However, there is an ongoing debate about the optimal approach for integrating this strategy. OBJECTIVES: To evaluate the association of neoadjuvant ICIs with pathologic complete response (pCR) across molecular phenotypes, to quantify the survival benefits of ICIs beyond pCR status, and to estimate the incidence of specific adverse events. DATA SOURCES: The PubMed database was searched on December 10, 2023, to identify all potential eligible studies. STUDY SELECTION: Randomized clinical trials (RCTs) that assessed (neo)adjuvant ICI plus chemotherapy in early breast cancer. DATA EXTRACTION AND SYNTHESIS: Data from the eligible RCTs were extracted by 2 reviewers. An extracted individual patient data meta-analysis and a trial-level random-effect meta-analysis were performed. MAIN OUTCOME(S) AND MEASURE(S): Outcomes were pCR, event-free survival (EFS) in patients with and without pCR, and adverse events. Hazard ratios were estimated using stratified Cox proportional hazards regression models. RESULTS: Nine RCTs involving 5114 patients met the inclusion criteria (2097 triple-negative breast cancer [TNBC], 1924 hormone receptor-positive [HR+]/ERBB2-negative [ERBB2-], and 1115 ERBB2+ tumors). In TNBC, the addition of ICIs was associated with an improved pCR rate regardless of programmed cell death ligand 1 (PD-L1) status (absolute improvement, >10%). In HR+/ ERBB2- tumors, the administration of ICIs was associated with improved pCR only in the PD-L1-positive (PD-L1+) population (absolute improvement, +12.2%), whereas no benefit was observed in ERBB2+ tumors. In patients with TNBC achieving a pCR, the addition of ICIs was associated with improved EFS (hazard ratio, 0.65; 95% CI, 0.42-1.00), resulting in a 5-year EFS of 92.0% with ICIs compared with 88.0% without them. In patients with residual disease, ICIs also showed better EFS (hazard ratio, 0.77; 95% CI, 0.61-0.98), resulting in a 5-year EFS of 63.3% with ICIs and 56.1% without them. Adjuvant ICI did not show numerical improvement in patients with either pCR or residual disease (all hazard ratios >1). During the neoadjuvant treatment, the incidence of grade 3 or greater immune-related adverse events with ICI was 10.3%. CONCLUSIONS AND RELEVANCE: These findings suggest that neoadjuvant ICI therapy improves efficacy outcomes in early-stage TNBC and PD-L1+ HR+/ERBB2- tumors with an acceptable safety profile; however, no benefit was observed with adjuvant ICI. Given the financial and toxicity costs associated with ICIs, future research should prioritize identifying patients most likely to benefit from the addition of ICIs to neoadjuvant chemotherapy.
引用
- Villacampa G, Navarro V, Matikas A, et al. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024. PMID: 39207778. doi:10.1001/jamaoncol.2024.3456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。